Kewan, T., Bewersdorf, J. P., Lanino, L., Blaha, O., Stempel, J., Ali, N. A., DeZern, A., Sekeres, M., Uy, G., Urrutia, S., Carraway, H., Desai, P., Griffiths, E., Stein, E., Brunner, A., McMahon, C., Shallis, R., Zeidner, J., Savona, M., Chandhok, N., Logothetis, C., Bidikian, A., Getz, T., Roboz, G., Rolles, B., Wang, E., Harris, A., Amaya, M., Hawkins, H., Ball, S., Grenet, J., Xie, Z., Madanat, Y., Abaza, Y., Badar, T., Campos, J., Haferlach, T., Maciejewski, J., Enjeti, A., Al-Rabi, K., Halahleh, K., Hiwase, D., Diez-Campelo, M., Valcárcel, D., Haferlach, C., Pleyer, L., Kotsianidis, I., Pappa, V., Santini, V., Consagra, A., Al-Kali, A., Ogawa, S., Nannya, Y., Komrokji, R., Stahl, M., Porta, M. D., Sallman, D., Zeidan, A. (2025). Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database. Blood. https://doi.org/10.1182/blood-2025-3863